1. Home
  2. MREO vs AGS Comparison

MREO vs AGS Comparison

Compare MREO & AGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • AGS
  • Stock Information
  • Founded
  • MREO 2015
  • AGS 2005
  • Country
  • MREO United Kingdom
  • AGS United States
  • Employees
  • MREO N/A
  • AGS N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • AGS Miscellaneous manufacturing industries
  • Sector
  • MREO Health Care
  • AGS Consumer Discretionary
  • Exchange
  • MREO Nasdaq
  • AGS Nasdaq
  • Market Cap
  • MREO 438.8M
  • AGS 508.0M
  • IPO Year
  • MREO N/A
  • AGS 2018
  • Fundamental
  • Price
  • MREO $2.87
  • AGS N/A
  • Analyst Decision
  • MREO Strong Buy
  • AGS Hold
  • Analyst Count
  • MREO 5
  • AGS 1
  • Target Price
  • MREO $7.60
  • AGS $12.50
  • AVG Volume (30 Days)
  • MREO 1.3M
  • AGS 506.1K
  • Earning Date
  • MREO 08-12-2025
  • AGS 08-06-2025
  • Dividend Yield
  • MREO N/A
  • AGS N/A
  • EPS Growth
  • MREO N/A
  • AGS 852.53
  • EPS
  • MREO N/A
  • AGS 1.16
  • Revenue
  • MREO N/A
  • AGS $393,717,000.00
  • Revenue This Year
  • MREO N/A
  • AGS $4.30
  • Revenue Next Year
  • MREO $52.34
  • AGS $5.14
  • P/E Ratio
  • MREO N/A
  • AGS $10.49
  • Revenue Growth
  • MREO N/A
  • AGS 6.60
  • 52 Week Low
  • MREO $1.58
  • AGS $11.09
  • 52 Week High
  • MREO $5.02
  • AGS $12.51
  • Technical
  • Relative Strength Index (RSI)
  • MREO 61.43
  • AGS 1.52
  • Support Level
  • MREO $2.63
  • AGS $12.36
  • Resistance Level
  • MREO $2.85
  • AGS $12.51
  • Average True Range (ATR)
  • MREO 0.16
  • AGS 0.03
  • MACD
  • MREO -0.01
  • AGS -0.79
  • Stochastic Oscillator
  • MREO 79.41
  • AGS 0.00

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About AGS PlayAGS Inc.

PlayAGS Inc is a designer and supplier of gaming products and services for the gaming industry. The company mainly supplies electronic gaming machines (EGM), server-based systems and back-office systems which are used by casinos, and various gaming locations. Its operating segments are EGM, Table Products, and Interactive. The EGM segment offers a selection of video slot titles developed for the world-wide marketplace as well as EGM cabinets. Its Table Products segments include live proprietary table games and side bets, as well as ancillary table products. The Interactive segment consists of delivering games through mobile apps such as Lucky Play Casino and Vegas Fever. It earns a majority of its revenue from Electronic Gaming Machines segment and geographically from the United States.

Share on Social Networks: